SottoPelle® Learning Center

2023 marked a year of significant progress in the field of HRT. Research advancements, clinical trials, and increased awareness are paving the way for more personalized, effective, and accessible treatment options for physicians administering hormone replacement therapy to improve their patients’ health and quality of life.

While progesterone has long been considered exclusively a female reproductive hormone, numerous studies now show that it has wide ranging neuroprotective properties in humans. In this article, we share some revelatory research on progesterone replacement therapy to improve neurological outcome after traumatic brain injury.

After age 40, men’s testosterone levels will begin to decrease. This decrease is linked to an increase in mortality and cardiovascular risks, as well as a greater risk of developing type 2 diabetes, coronary artery disease (CAD), and metabolic syndrome. Testosterone replacement can improve many of the cardiovascular diseases of older men.

Over 116 million Americans, roughly 35% of the population, are aged 50 and over. And this will swell to 160 million by 2040, nearly 40% of the population. Preparing for this demographic revolution is a necessity for physicians who wish to better serve their patients’ needs in addition to growing their practice.

Many physicians are less familiar with dosing of male hormones in female patients. As a result, testosterone replacement in women is sometimes avoided by doctors when it could provide substantial improvements in female patients’ health.

30% of the US female population is postmenopausal. Clinical studies support what we’ve known all along: bioidentical hormone replacement therapy can significantly improve quality of life of postmenopausal women.